Viruses with low Rev functional activity replicate poorly compared to viruses with high Rev functional activity. by Godfrey A. Dzhivhuho (5563517)

Subjects:

Burden of any-form tobacco use in districts of India among males according to NFHS 4 and 5^¶. by Shibaji Gupta (19928927)

Subjects:

Expression pattern of CD47 in non-small cell lung cancer tissues. by Hefeng Zhang (1506811)

Subjects:

Distribution of job schedules among respondents. by Alaa Mathkour (21273162)

Subjects:

Mean movement counts of uninfected and <i>P. yoelii</i>-infected <i>A. stephensi</i> provisioned with histamine + 5-HT. by Kevin O. Ochwedo (11032248)

Subjects:

Forest plots of stratified analyses of AAR and 28-day mortality. by Yanping Wang (275956)

Subjects:

Three feature extraction methods used in S_628 comparison of results. by Bo Han (84102)

Subjects:

RCS regression analysis of AAR and in-hospital mortality in the eICU-CRD. by Yanping Wang (275956)

Subjects:

Construction and characterization of an HIV proviral clone with an interchangeable <i>rev</i> gene. by Godfrey A. Dzhivhuho (5563517)

Subjects:

Supplementary file 1_Cistanche tubulosa glycosides ameliorate cognitive decline in APP/PS1 mice via modulation of gut microbiota and fatty acid metabolism: insights from multi-omic... by Rui Hou (161624)

“…</p>Results<p>GCT treatment significantly improved spatial memory and reduced the protein levels of Aβ and proinflammatory factors in APP/PS1 mice. …”

Data Sheet 1_Prevalence and risk of thyroid disease among adult primary aldosteronism patients: a systematic review, meta-analysis, and trial sequential analysis.docx by Wansong Hu (13244919)

“…While the overall prevalence of thyroid diseases was higher in PA patients (OR: 1.33, 95% CI: 1.03-1.71, p=0.03), subgroup analysis revealed that this association was primarily driven by a significantly increased prevalence of thyroid nodules (OR: 1.85, 95% CI: 1.23-2.80, p=0.003). …”

Image 1_Relationship Between Nucleos(t)ide analogue antiviral response time and prognosis in Chronic Hepatitis B: conclusions depend on baseline viral load and HBeAg status.jpeg by Jingtao Huang (6522704)

“…Only the after-96-week group showed a significant increase in maintained virological response rate (p = 0.04).…”

Table 1_Relationship Between Nucleos(t)ide analogue antiviral response time and prognosis in Chronic Hepatitis B: conclusions depend on baseline viral load and HBeAg status.docx by Jingtao Huang (6522704)

“…Only the after-96-week group showed a significant increase in maintained virological response rate (p = 0.04).…”

Image 6_Risk of new-onset inflammatory bowel disease in psoriasis patients treated with five different interleukin inhibitors: a systematic review and meta-analysis.png by Jia-Xin Zhang (1833157)

“…</p>Conclusions<p>There is insufficient evidence to confirm that Ustekinumab, Bimekizumab, Secukinumab, and Brodalumab significantly increase the risk of new-onset IBD. However, compared to the control group, Ixekizumab was significantly associated with an increased risk of new-onset IBD in psoriasis patients. …”

Image 3_Risk of new-onset inflammatory bowel disease in psoriasis patients treated with five different interleukin inhibitors: a systematic review and meta-analysis.png by Jia-Xin Zhang (1833157)

“…</p>Conclusions<p>There is insufficient evidence to confirm that Ustekinumab, Bimekizumab, Secukinumab, and Brodalumab significantly increase the risk of new-onset IBD. However, compared to the control group, Ixekizumab was significantly associated with an increased risk of new-onset IBD in psoriasis patients. …”

Image 4_Risk of new-onset inflammatory bowel disease in psoriasis patients treated with five different interleukin inhibitors: a systematic review and meta-analysis.png by Jia-Xin Zhang (1833157)

“…</p>Conclusions<p>There is insufficient evidence to confirm that Ustekinumab, Bimekizumab, Secukinumab, and Brodalumab significantly increase the risk of new-onset IBD. However, compared to the control group, Ixekizumab was significantly associated with an increased risk of new-onset IBD in psoriasis patients. …”

Image 5_Risk of new-onset inflammatory bowel disease in psoriasis patients treated with five different interleukin inhibitors: a systematic review and meta-analysis.png by Jia-Xin Zhang (1833157)

“…</p>Conclusions<p>There is insufficient evidence to confirm that Ustekinumab, Bimekizumab, Secukinumab, and Brodalumab significantly increase the risk of new-onset IBD. However, compared to the control group, Ixekizumab was significantly associated with an increased risk of new-onset IBD in psoriasis patients. …”

Table 1_Risk of new-onset inflammatory bowel disease in psoriasis patients treated with five different interleukin inhibitors: a systematic review and meta-analysis.docx by Jia-Xin Zhang (1833157)

“…</p>Conclusions<p>There is insufficient evidence to confirm that Ustekinumab, Bimekizumab, Secukinumab, and Brodalumab significantly increase the risk of new-onset IBD. However, compared to the control group, Ixekizumab was significantly associated with an increased risk of new-onset IBD in psoriasis patients. …”

Image 1_Risk of new-onset inflammatory bowel disease in psoriasis patients treated with five different interleukin inhibitors: a systematic review and meta-analysis.png by Jia-Xin Zhang (1833157)

“…</p>Conclusions<p>There is insufficient evidence to confirm that Ustekinumab, Bimekizumab, Secukinumab, and Brodalumab significantly increase the risk of new-onset IBD. However, compared to the control group, Ixekizumab was significantly associated with an increased risk of new-onset IBD in psoriasis patients. …”

Table 2_Risk of new-onset inflammatory bowel disease in psoriasis patients treated with five different interleukin inhibitors: a systematic review and meta-analysis.docx by Jia-Xin Zhang (1833157)

“…</p>Conclusions<p>There is insufficient evidence to confirm that Ustekinumab, Bimekizumab, Secukinumab, and Brodalumab significantly increase the risk of new-onset IBD. However, compared to the control group, Ixekizumab was significantly associated with an increased risk of new-onset IBD in psoriasis patients. …”